1	Medicaid Expansion and Survival Outcomes among Men with Prostate
2	Cancer
3	Oluwasegun Akinyemi <sup>1,2</sup> , Mojisola Fasokun <sup>3</sup> , Eric Hercules <sup>1</sup> , Seun Ikugbayigbe <sup>4</sup> , Eunice
4	Odusanya <sup>1</sup> , Nadia Hackett <sup>1</sup> , Oluebubechukwu Eze <sup>1</sup> , Lerone Ainsworth <sup>5</sup> , Kakra Hughes <sup>5</sup> , Edward
5	Cornwell III <sup>5</sup> Pamela Coleman <sup>5</sup>
6	
7	<sup>1</sup> Department of Surgery Outcomes Research Center, Howard University College of Medicine,
8	Washington DC, USA
9	<sup>2</sup> Department of Health Policy and Management, University of Maryland College Park, MD, USA
10	<sup>3</sup> Department of Epidemiology, University of Alabama at Birmingham, AL, USA
11	<sup>4</sup> Department of Public Health, Eastern Illinois University, Charleston., IL, USA
12	<sup>5</sup> Department of Surgery, Howard University College of Medicine, Washington DC, USA
13	
14	Short Title: Medicaid Expansion and Prostate Cancer Survival

# 15 ABSTRACT

- 16 INTRODUCTION: Prostate cancer stands as one of the most diagnosed malignancies among
- 17 men worldwide. With the recent expansion of Medicaid under the Affordable Care Act (ACA),
- 18 millions more Americans now have health insurance coverage, potentially influencing healthcare
- 19 access and subsequent outcomes for various illnesses, including prostate cancer. Yet, the direct
- 20 correlation between Medicaid expansion and cancer-specific survival, particularly for early-stage
- 21 prostate cancer, remains an area warranting comprehensive exploration.

22 OBJECTIVE: This study aims to determine the impact of the implementation of Medicaid

- 23 expansion on Survival outcomes among men with prostate cancer.
- 24 METHODS: We utilized data from the SEER registry to determine the causal impact of the

25 implementation of the ACA on outcomes among men with prostate cancer. The study covered

26 the years 2003-2021, divided into pre-ACA (2003-2009) and post-ACA (2015-2021) periods,

27 with a 1-year washout (2014-2015) since Medicaid expansion was implemented in 2014 in

28 Kentucky. Using a Difference-in-Differences approach, we compared survival among men with

29 prostate cancers from Kentucky to Georgia. We adjusted for patient demographics, income,

30 metropolitan status, disease stage, and treatment modalities.

31 RESULTS: We analyzed a cohort of 68,222 men with prostate cancer during the study period.

32 Of these, 37,810 (55.4%) were diagnosed in the pre-ACA period, with 70.8% from Georgia and

33 29.2% from Kentucky. The remaining 30,412 (44.6%) were diagnosed in the post-ACA period,

- 34 with 72.3% from Georgia and 27.7% from Kentucky. Medicaid expansion in Kentucky was
- 35 associated with a 16.8% reduction in hazard of death (HD), indicating improved overall survival

36 among low-income individuals. This trend was consistent across different racial/ethnic groups.

37 Specifically, Non-Hispanic white men experienced a 16.2% reduction (DID = -0.162, 95% CI: -

- 38 0.315 to -0.008), Non-Hispanic Black men had a 17.9% reduction (DID = -0.179, 95% CI: -
- 39 0.348 to -0.009), and Hispanic men saw a 15.9% reduction (DID = -0.159, 95% CI: -0.313 to -
- 40 0.005) in HD among low-income individuals.
- 41 CONCLUSION: Medicaid Expansion was associated with a substantive improvement in overall
- 42 survival among men with prostate cancers in Kentucky compared to non-expansion Georgia.

43

# 45 INTRODUCTION

46 Outside of skin cancer, prostate cancer is the most common cancer in men in the United States 47 (U.S.) [1], with approximately 299,010 new cases of prostate cancer expected in 2024, along 48 with about 35,250 deaths from the disease [2]. Since 2014, the incidence rate has sharply 49 increased 3% per year overall and 5% per year for advanced-stage prostate cancer [2]. For men 50 diagnosed with prostate cancer, the treatment can range from observation, curative surgery 51 (prostatectomy), and targeted radiation therapy [3], however, what is not often discussed are the 52 factors that determine the treatment of choice [3,4]. Financial toxicity is a term that is used to 53 describe the financial consequences and the potential stress incurred by a disease diagnosis and 54 treatment [5]. In 2020 alone, there was an estimated \$22.3 billion spent on prostate cancer care, 55 with the majority of that being made up by direct medical expenses [6]. However, the economic 56 impact goes far beyond medical bills. Prostate cancer leads to very significant lost earnings as a 57 result of premature mortality and the inability of patients to work during their treatment and 58 recovery process [7].

59

60 Prostate cancer is a very complex disease whose pathogenesis involves both genetic and 61 environmental factors and is mainly driven by alterations in androgen signaling [8]. There are a 62 multitude of risk factors that contribute to the development of prostate cancer, including age, 63 family history, and race [9]. African American men are at a higher risk of developing prostate 64 cancer and usually tend to present with a more advanced disease at diagnosis compared to their 65 counterparts [10]. It has also been shown that social determinants of health (SDOH) have a 66 significant impact on prostate cancer outcomes(11). Factors such as socioeconomic status, access 67 to healthcare, and living conditions not only influence the state at which prostate cancer is

diagnosed, but also overall survival rates [12]. Prior data suggests that incidence rates are
associated with socioeconomic status [10]. Additionally, lower socioeconomic status is
associated with poorer survival rates [10]. In order to reduce disparities in prostate cancer care
and improve survival, it is crucial to address the SDOH that may be impacting the outcomes of
disease.

73 The goal of Medicaid, initially enacted in 1965, was to allow States to receive federal funding to 74 provide health insurance to persons with limited income [13]. This legislation was later expanded 75 and termed The Affordable Care Act (ACA), passed in 2010 and fully implemented in 2014 [14]. 76 This legislation addressed Americans without health insurance facing systemic health 77 inequalities [14]. This act is the most significant expansion of coverage in the US healthcare 78 system following the creation of Medicare and Medicaid in 1965 [15]. Before the ACA, there 79 were limitations to Medicaid eligibility on the state level, which covered only the poorest in 80 specific categories (i.e., disabled people, pregnant women, and children) [15]. In contrast, with 81 the ACA, citizens with income at or below 138% of the federal poverty line qualify for aid [14]. 82 Due to ACA, the number of uninsured individuals declined significantly from 2013 to 2022, 83 from approximately 45.2 million to 26.4 million [5]. The overall implementation of the 84 Affordable Care Act during 2013-2022 has led to an overall 45% increase in Americans with 85 health insurance coverage [16]. 86 When looking specifically at the effect of the ACA on patients newly diagnosed with breast, 87 colorectal, and lung cancer from 2012 to 2015 there has been an increase in earlier stage of 88 diagnosis and lower hazard of mortality among patients [17]. A study done written by Eugia et al

89 assessed the effect of Medicaid expansion in states with coverage in patients with bladder,

90 colorectal, esophageal, lung, bladder and gastric cancers and found that there was a increase in

91 number patients who had access to healthcare and noted a positive effect on access and
92 utilization of oncologic care [18]. We understand the significance of the implementation of the
93 affordable care act on the improved access of care utilization, however direct correlation between
94 Medicaid expansion and cancer-specific survival, particularly for early-stage prostate cancer,
95 remains an area warranting comprehensive exploration. This study aims to determine the impact
96 of the implementation of the Affordable Care Act on cancer-specific survival among men with
97 early-stage prostate malignancies.

# 98 METHODOLOGY

## 99 Data Source and Study Population

100 This retrospective cohort study utilized data from the Surveillance, Epidemiology, and End 101 Results (SEER) database, focusing on men diagnosed with prostate cancer between 2000 and 102 2021[19]. SEER collects cancer incidence and survival data from population-based cancer 103 registries covering approximately 48% of the U.S. population as of 2021 [20]. The study utilized 104 the "Incidence - SEER 18 Registries, Nov 2021 Sub (2000-2021)" database [19]. Inclusion 105 criteria included: (1) men diagnosed with prostate malignancies identified using International 106 Classification of Diseases for Oncology, 3rd edition (ICD-O-3) codes; (2) patients with complete 107 clinicopathological information and survival data; (3) age at diagnosis between 18 - 64yrs; and 108 (4) patients actively followed up. Exclusion criteria were: (1) patients diagnosed through autopsy 109 or death certificate only, or with clinical diagnoses only; (2) patients with missing data on 110 race/ethnicity, household median income, state identification, or years of follow-up. This study 111 involved publicly available data and did not include any identifiable patient information, so

# institutional review board approval was not required. Informed consent was also not necessary due to the retrospective nature of the study.

# 114 Georgia vs. Kentucky

115 Georgia (control state) and Kentucky (treated state) were selected for the study due to their

116 contrasting approaches to healthcare policy, specifically regarding the implementation of the

117 Affordable Care Act (ACA). Kentucky expanded Medicaid under the ACA in 2014, leading to a

significant increase in Medicaid/CHIP enrollment and a reduction in the uninsured rate. In

119 contrast, Georgia did not expand Medicaid, resulting in higher uninsured rates and more

120 restrictive access to healthcare services. The differences in healthcare policy between the two

121 states provide a unique opportunity to assess the impact of the ACA on prostate cancer

122 outcomes, particularly cancer-specific survival and overall survival.

## 123 Primary Outcome of Interest

124 The primary outcomes of interest were cancer-specific survival (CSS) and overall survival (OS).

125 CSS was defined as the time from diagnosis to death due to prostate cancer, while OS referred to

126 the time from diagnosis to death from any cause. Both outcomes were assessed over two periods:

127 pre-ACA (2003-2009) and post-ACA (2015-2021).

# 128 Independent Variables of Interest

129 The primary independent variables were the implementation of the ACA and Medicaid

expansion, categorized into two time periods: pre-ACA (2003-2009) and post-ACA (2015-2021)

131 with a 1-year washout period of January 2014- December 2014 to allow for the policy to become

132 fully operational. Kentucky's Medicaid expansion served as the treatment, while Georgia, which

133 did not expand Medicaid, served as the control. The interaction between state and time period

134 (State X ACA) was used to evaluate the differential impact of the ACA on prostate cancer135 outcomes between the two states.

## 136 Covariates

137 Covariates included demographic factors such as age at diagnosis (continuous variable),

138 race/ethnicity (categorized as Non-Hispanic White people, Non-Hispanic Black people, Hispanic

139 people, Non-Hispanic Asian/Pacific Islander people, and Native American people), and marital

140 status (categorized as married, widowed, divorced, separated, or unknown). Socioeconomic

141 status was assessed using household median income (>\$64,000 and  $\leq$ \$64,000). Tumor

142 characteristics, including stage at diagnosis (localized, regional, distant), and treatment

143 modalities (prostatectomy, chemotherapy, radiation) were also included as covariates.

#### 144 Theoretical Model: Andersen Behavioral Model

145 This study uses the Andersen Behavioral Model of Health Services [21, 22] Use to explore the

146 impact of the ACA and Medicaid expansion on prostate cancer mortality, comparing Kentucky

147 (which implemented Medicaid expansion in 2014) and Georgia (which has not). The model

148 categorizes factors into predisposing, enabling, and need factors:

149 Predisposing Factors: These include demographics such as age (18-45, 45-64 years),

150 race/ethnicity (White, Black, Hispanic, etc.), and marital status (single, married, etc.), which

151 influence healthcare-seeking behavior.

152 Enabling Factors: These are resources that facilitate access to care, including income (<64K,

153  $\geq$  64K), metropolitan status (rural, small, medium, large metropolitan), and the state of residence

154 (Louisiana vs. Georgia), reflecting the impact of Medicaid expansion.

- 155 Need Factors: These include clinical variables such as cancer grade (Stage I, Stage II, Stage III)
- and Stage IV), and the receipt of treatments like surgery, chemotherapy, and radiotherapy, all of
- 157 which influence prostate cancer outcomes.

# 158 Difference-in-Differences (DID) Specification

- 159 The present study used a DID model to estimate the impact of Medicaid expansion on prostate
- 160 cancer outcomes; overall survival, overall deaths, and disease stage at presentation by comparing
- 161 Kentucky (treatment group, which implemented Medicaid expansion) to Georgia (control group,
- 162 which did not) during the pre-ACA and post-ACA periods. The variable ACA was set to 1 for
- 163 the post-Medicaid expansion period (2015–2020) and 0 for the pre-expansion period (2003-
- 164 2009). The variable State was defined as 1 if the observation was from Kentucky (expansion
- state) and 0 if from Georgia (non-expansion state).
- 166 The DID model is specified as:
- 167  $y=X\beta+\beta_1\cdot ACA+\beta_2\cdot State + \beta_{12}\cdot (ACA \times State) + u$  [23]
- 168 *y* represents the breast cancer outcome of interest (e.g., survival, overall mortality, or disease169 stage at presentation).
- 170 *X* includes covariates such as age, race, marital status, and treatment modalities.
- 171  $\beta_1$  captures the difference in outcomes between the pre- and post-ACA periods across both states.
- 172  $\beta_2$  captures the baseline difference between Louisiana and Georgia.
- 173  $\beta_{12}$  represents the effect of Medicaid expansion on breast cancer outcomes.
- 174 The interaction term ACA × State (i.e.,  $\beta_{12}$ ) estimates the difference in the change in outcomes
- 175 between Louisiana (the expansion state) and Georgia (the non-expansion state) from the pre- to
- 176 the post-ACA period. This term provides the key estimate of the impact of Medicaid expansion.
- 177 Statistical Analysis
- 178 Descriptive statistics summarized the characteristics of the study population. Chi-square tests
- 179 were used for categorical variables, and appropriate regression models, such as the Cox
- 180 proportional hazards model, were applied to time-to-event data. Margins plots were generated to

visualize the adjusted probabilities of each outcome across states and time periods. Subsequently,
the "lincom" command was used to calculate the DID and generate the standard error, p-value,
and confidence intervals. Statistical significance was determined using two-tailed tests with an

alpha level of 0.05. All analyses were conducted using STATA 16 statistical software.

185 RESULT

# **186 Baseline Study Characteristics**

187 In Table 1, the baseline characteristics of individuals with prostate cancer in Georgia and

188 Kentucky were compared across two time periods, pre-ACA (2003-2009) and post-ACA (2015-

189 2021). In the pre-ACA period, the mean age of diagnosis was similar between the two states,

190 with Georgia at  $57.3 \pm 5.2$  years and Kentucky at  $57.6 \pm 5.0$  years. Post-ACA, the mean age

slightly increased in both states, with Georgia at  $58.1 \pm 4.8$  years and Kentucky at  $58.4 \pm 4.7$ 

192 years. In terms of race and ethnicity, Georgia had a significantly higher proportion of Non-

193 Hispanic Black people compared to Kentucky in both periods. Pre-ACA, 37.0% of patients in

194 Georgia were Non-Hispanic Black people, compared to only 10.5% in Kentucky. Post-ACA, the

195 proportion of Non-Hispanic Black people in Georgia further increased to 47.7%, while in

196 Kentucky, it remained relatively low at 14.2%.

197 In terms of tumor stage at diagnosis, the proportion of localized cases decreased significantly in

both states post-ACA. In Georgia, localized cases dropped from 85.8% pre-ACA to 77.2% post-

ACA, while in Kentucky, they decreased from 80.5% to 68.5%. Additionally, the incidence of

distant-stage prostate cancer increased in both states post-ACA, rising from 2.7% to 5.2% in

201 Georgia and from 2.8% to 4.6% in Kentucky. Metropolitan status also revealed significant

differences, with a higher proportion of patients in Kentucky residing in rural areas compared to
Georgia during both periods. For example, in the post-ACA period, 23.0% of patients in
Kentucky lived in rural areas not adjacent to metropolitan areas, compared to only 4.2% in
Georgia.

# 206 Factor associated with CSS

207 Table 2 reveals factors associated with CSS among individuals with prostate cancer; comparing

208 Georgia and Kentucky across pre-ACA and post-ACA periods. The post-2015 period was

associated with improved survival outcomes, with a hazard ratio (HR) of 0.78 (95% CI: 0.68–

210 0.89), indicating a significant reduction in the risk of cancer-specific mortality. Additionally, the

211 interaction between states and the post-Medicaid expansion period revealed that individuals in

212 Kentucky had a substantial reduction in mortality post-expansion period (HR = 0.71, 95% CI:

213 0.56–0.90), suggesting a beneficial effect of the policy in reducing cancer-specific mortality in

this state.

215 Other covariates also played a critical role in the CSS. Older age (45-64yrs) was associated with

216 increased mortality (HR = 1.44, 95% CI: 1.00-2.07), while being married was protective (HR =

217 0.65, 95% CI: 0.58–0.74). Racial disparities were evident, with Non-Hispanic Black people

218 having a higher risk of mortality (HR = 1.10, 95% CI: 1.00–1.22) compared to Non-Hispanic

219 White people. Socioeconomic factors, such as living in large metropolitan areas, were associated

with improved survival (HR = 0.74, 95% CI: 0.63-0.87). Advanced cancer stages were strongly

associated with worse outcomes, with stage IV having the highest mortality risk (HR = 26.99,

222 95% CI: 11.85–61.46). Additionally, treatment factors such as receiving a prostatectomy

significantly reduced the risk of mortality (HR = 0.38, 95% CI: 0.33-0.43), while chemotherapy

and radiation were associated with increased mortality risk (HR = 1.62, 95% CI: 1.39–1.89; HR
= 1.20, 95% CI: 1.09–1.33, respectively).

# 226 Factors associated with Overall survival

In table 3, it reports the factors associated with the overall survival among individuals with prostate cancers in both states and in both time periods. The post-2015 period was associated with improved overall survival, with a hazard ratio (HR) of 0.90 (95% CI: 0.82-0.99), indicating a significant reduction in the risk of overall mortality during the period. The interaction between state and post-Medicaid expansion period showed that individuals in Kentucky had a reduction in mortality post-ACA (HR = 0.87, 95% CI: 0.75-1.01), although this effect was marginally

233 significant (p = 0.065).

234 Other covariates also played a crucial role in overall survival. Age between 45-64yrs. was

significantly associated with higher mortality (HR = 2.17, 95% CI: 1.69-2.81), while being

236 married was also protective (HR = 0.65, 95% CI: 0.61-0.70). Racial disparities were evident,

with Non-Hispanic Black people having a higher risk of mortality (HR = 1.10, 95% CI: 1.04–

238 1.17) compared to Non-Hispanic White people. Socioeconomic factors, such as living in large

239 metropolitan areas, were associated with improved survival (HR = 0.71, 95% CI: 0.65-0.78).

Advanced cancer stages were strongly associated with worse outcomes, with stage IV having the

highest mortality risk (HR = 4.05, 95% CI: 2.99–5.48). Additionally, treatment factors such as

receiving a prostatectomy significantly reduced the risk of mortality (HR = 0.47, 95% CI: 0.44–

243 0.51), while chemotherapy was associated with increased mortality risk (HR = 1.42, 95% CI:

**244** 1.24–1.62).

#### 245 Predicted Probabilities (CSS)

246 Table 4 reveals the predicted probabilities of the hazards of death for CSS between Georgia and 247 Kentucky in the pre-ACA and post-ACA across different races/ethnicities and in the overall 248 populations. In both states and across all races and ethnicities, the post-2015 period was 249 associated with an improvement in CSS. Specifically, for the overall population, the probability 250 of death decreased from 5.41 (95% CI: 1.55-9.28) in the pre-ACA period to 4.22 (95% CI: 1.10-251 7.35) in the post-ACA period in Georgia and from 6.02 (95% CI: 1.63-10.41) to 3.34 (95% CI: 252 0.80-5.88) in Kentucky. Among Non-Hispanic White people, the probabilities followed a similar 253 trend, with the post-ACA period showing reduced risks compared to the pre-ACA period, such 254 as in Kentucky, where the probability decreased from 5.79 (95% CI: 1.58-10.00) to 3.21 (95% 255 CI: 0.78-5.65). Non-Hispanic Black people also experienced a reduction in the predicted 256 probabilities of death post-ACA, with a decrease from 6.39 (95% CI: 1.69-11.09) to 3.54 (95% 257 CI: 0.82-6.27) in Kentucky. Hispanic people, Non-Hispanic Asian/Pacific Islander people, and 258 Native American people also showed a reduction in the post-ACA period across both states.

# 259 Predicted Probabilities (Overall Survival)

260 Table 5 shows the predicted probabilities of overall survival between Georgia and Kentucky in

the pre-ACA and post-ACA periods across racial and ethnic groups. In the overall population,

the post-2015 period in Georgia experienced a reduction in the probability of death from 1.06

263 (95% CI: 0.81-1.31) pre-ACA to 0.95 (95% CI: 0.70-1.21) post-ACA. Similarly, in Kentucky,

- the probability of death decreased from 1.25 (95% CI: 0.94-1.56) pre-ACA to 0.98 (95% CI:
- 265 0.70-1.26) post-ACA. Among Non-Hispanic White people, a similar trend was observed, with
- 266 the pre-ACA probability decreasing from 1.02 (95% CI: 0.78-1.26) to 0.92 (95% CI: 0.67-1.17)
- 267 in Georgia and from 1.21 (95% CI: 0.91-1.51) to 0.94 (95% CI: 0.67-1.22) in Kentucky.

**268** For Non-Hispanic Black people, the predicted probability of death post-ACA decreased from

269 1.13 (95% CI: 0.86-1.40) to 1.02 (95% CI: 0.74-1.29) in Georgia and from 1.33 (95% CI: 0.99-

270 1.67) to 1.04 (95% CI: 0.73-1.35) in Kentucky. Hispanic people also experienced a decrease in

271 the probability of death, particularly in Kentucky, where the post-ACA period saw a reduction

272 from 1.00 (95% CI: 0.69-1.32) to 0.91 (95% CI: 0.60-1.21). This pattern was also seen among

273 Non-Hispanic Asian/Pacific Islander people and Native Americans people.

# 274 DID for Cancer-Specific Survival

Table 6 reports the DID output on the change in the hazard of death for CSS among individuals

with prostate cancer. Overall, the coefficient for all individuals was -1.49 (95% CI: -3.00 to 0.02,

277 p=0.053), indicating a marginally significant reduction in the hazard of death. When broken

down by race/ethnicity, Non-Hispanic White people showed a similar reduction (Coef. = -1.44,

279 95% CI: -2.89 to 0.01, p=0.052), as did Non-Hispanic Black people (Coef. = -1.58, 95% CI: -

280 3.19 to 0.02, p=0.054), both nearing statistical significances. Hispanic people also experienced a

**281** reduction in hazard (Coef. = -1.24, 95% CI: -2.55 to 0.08, p=0.065), though the result was

slightly less significant. The reduction was more pronounced for NHAPI people (Coef. = -1.76,

283 95% CI: -3.84 to 0.31, p=0.096), though it did not reach statistical significance. Native

Americans showed the least reduction in hazard, with a coefficient of -0.67 (95% CI: -2.14 to

**285** 0.81, p=0.376), indicating no significant change.

# 286 DID for Overall Cancer Survival

Table 7 reveals the DID results on the change in the hazard of death for overall survival among

288 individuals with prostate cancers. There was a substantive reduction in mortality risk across most

289 racial and ethnic groups post-Medicaid expansion in Kentucky compared to Georgia. For the

290 overall population, the analysis showed a modest but statistically significant decrease in the

291	hazard of death, with a coefficient of -0.17 (95% CI: -0.33 to -0.01, p=0.039). This trend was
292	consistent across Non-Hispanic White people (Coef. = -0.16, 95% CI: -0.32 to -0.01, p=0.039)
293	and Non-Hispanic Black people (Coef. = -0.18, 95% CI: -0.35 to -0.01, p=0.039) people, both of
294	which experienced significant reductions in mortality risk. Hispanic people also experienced a
295	significant reduction in hazard (Coef. = -0.16, 95% CI: -0.31 to -0.01, p=0.043). Non-Hispanic
296	Asian/Pacific Islander people showed a similar, though marginally significant, reduction (Coef. =
297	-0.12, 95% CI: -0.24 to 0.00, p=0.060). Native Americans had the smallest reduction, with a
298	coefficient of -0.07 (95% CI: -0.19 to 0.05, p=0.245), indicating no significant change in overall
299	survival.

# 300 DISCUSSION

301 Overall, there was a decline in the predicted probabilities of cancer-specific deaths in the post-302 2015 period, observed across both states regardless of Medicaid expansion status. However, this 303 trend was not mirrored in the risk of overall deaths, as no significant difference was noted 304 between the pre- and post-Medicaid expansion periods for overall survival in either state. While 305 a more pronounced reduction in cancer-specific mortality was noted in Kentucky compared to 306 Georgia, the difference was not statistically significant. Conversely, there was a significant 16.8 307 percentage point decrease in overall mortality risk among individuals with prostate cancer in 308 Kentucky relative to Georgia, with the reduction ranging from -32.6% to -9%. This improvement 309 in overall survival was consistent across different racial/ethnic groups and was particularly 310 notable among Black individuals, who experienced a 17.9 percentage point drop in the risk of 311 overall deaths compared to their counterparts in Georgia. Other significant predictors of 312 improved cancer-specific and overall survival included younger age, White race, higher 313 household median income, married status, and residence in metropolitan areas. Undergoing

314 prostatectomy was significantly associated with improved survival, while radiation therapy did 315 not show a significant effect. In contrast, chemotherapy was linked to worse cancer-specific and 316 overall survival, potentially due to higher disease burden among individuals receiving this 317 treatment modality.

318 The improvement in survival among individuals diagnosed with prostate cancer in recent years is 319 likely multifactorial. Advances in early detection and screening methods, particularly widespread 320 adoption of prostate-specific antigen (PSA) testing, have facilitated diagnosis at earlier, more 321 treatable stages. Additionally, innovations in treatment modalities—including the development 322 of more effective surgical techniques, radiotherapy, androgen deprivation therapy, and novel 323 targeted therapies—have significantly enhanced disease management. Increased access to 324 multidisciplinary care, improved supportive therapies, and heightened awareness of prostate 325 cancer through public health campaigns have also contributed to better outcomes. Furthermore, 326 there has been an overall improvement in healthcare delivery systems and a greater emphasis on 327 personalized treatment approaches tailored to patients' genetic and molecular profiles, which 328 may account for the observed survival gains.

329 When comparing the change in prostate cancer-specific mortality between Kentucky and

330 Georgia, there were no statistically significant differences, although the results indicated a trend

towards a greater decline in Kentucky. This suggests that while there may be a modest reduction

332 in prostate cancer-specific deaths following the implementation of the ACA and Medicaid

expansion in Kentucky, the findings do not provide robust evidence of a substantive

improvement in outcomes relative to Georgia.

335 The absence of a substantive impact of Medicaid expansion on prostate cancer outcomes in

336 Kentucky compared to Georgia may be attributed to several factors. Prostate cancer is generally

337 a slow-growing malignancy with a favorable prognosis, and the benefits of improved healthcare 338 access may take years to manifest in survival outcomes. The indolent nature of the disease, 339 coupled with high baseline survival rates, could dilute the measurable effects of policy changes 340 within the study timeframe. Moreover, while we observed a trend towards a greater decline in 341 prostate cancer-specific mortality in Kentucky, the lack of statistical significance suggests that 342 the improvement may be influenced by other concurrent healthcare advancements or 343 socioeconomic factors not directly related to Medicaid expansion. These nuances indicate that 344 longer follow-up periods or studies focusing on more aggressive cancers might be needed to 345 detect the full impact of Medicaid expansion on cancer-specific outcomes. 346 Kentucky, a Medicaid expansion state, demonstrated a significant 16.8% reduction in overall 347 mortality risk compared to Georgia, a non-expansion state. This is particularly notable because 348 overall mortality, unlike cancer-specific mortality, may more comprehensively capture the 349 broader benefits of Medicaid expansion, such as improved access to preventive care, 350 management of comorbidities, and timely interventions for acute conditions. Given the generally 351 indolent nature of prostate cancer, the impact of Medicaid expansion on prostate cancer-specific 352 deaths may take longer to manifest, whereas the significant reduction in all-cause mortality in 353 Kentucky suggests that enhanced healthcare access had an immediate and measurable effect on 354 broader health outcomes. 355 This finding is important in light of the fact that no statistically significant change in overall 356 mortality was observed across the study period in either state, emphasizing that the mortality

357 reduction in Kentucky may be directly attributable to increased healthcare access following the

358 implementation of the ACA and its Medicaid expansion component. These results highlight the

359 potential of Medicaid expansion to reduce health disparities and improve survival, particularly in

populations that were previously uninsured or underinsured, reinforcing the role of policy-drivenhealthcare reforms in enhancing population health outcomes.

362 Interestingly, individuals who received chemotherapy experienced a significantly higher hazard 363 of both cancer-specific and overall mortality. This may be explained by a higher disease burden 364 and more advanced cancer stage at the time of treatment, as chemotherapy is often reserved for 365 high-risk or metastatic cases. Additionally, the observed mortality risk may reflect an imbalance 366 in sociodemographic and clinical factors, as patients receiving chemotherapy were more likely to 367 belong to vulnerable groups such as low-income families, unmarried or single individuals, and 368 racial minorities—populations that often have limited access to comprehensive healthcare and 369 may present with more aggressive disease. Moreover, disparities in treatment adherence and 370 supportive care in these groups could further contribute to poorer outcomes, underscoring the 371 need for tailored interventions to address these inequities and improve survival among 372 chemotherapy-treated patients.

This study highlights persistent disparities in cancer outcomes, with Black individuals, those from the lowest-income households, single and unmarried individuals, and residents of rural areas facing the highest risk of both cancer-specific and overall mortality. These disparities may be driven by a combination of factors, including delayed diagnosis, limited access to high-quality care, and a greater burden of comorbidities in these populations. Additionally, socioeconomic barriers and geographical challenges often result in reduced access to advanced treatments and follow-up care, further exacerbating survival disparities.

**380** STRENGHT AND LIMITATIONS.

381 This study has several strengths, including the use of the SEER registry, a high-quality,

382 population-based cancer database that provides comprehensive clinical and demographic

383 information, allowing for robust analysis of cancer outcomes. A key strength is our approach of 384 comparing two states with similar demographic profiles—Kentucky and Georgia—rather than 385 grouping states broadly into Medicaid expansion versus non-expansion categories. This approach 386 mitigates the potential bias introduced by heterogeneity in Medicaid implementation timelines 387 and healthcare infrastructure across states, enhancing the specificity of our findings. 388 Furthermore, the use of a DID approach allows for stronger causal inferences from observational 389 data by accounting for underlying time trends, thus providing a more accurate estimate of the 390 impact of Medicaid expansion on survival outcomes. However, our study has limitations, 391 including the inability to control pre-existing comorbidities or baseline insurance status, which 392 may influence both treatment decisions and survival outcomes. Additionally, unmeasured factors 393 such as differences in healthcare delivery systems, patient adherence, and provider practices 394 could also affect mortality and potentially confound our results. Despite these limitations, our 395 study offers valuable insights into the nuanced effects of Medicaid expansion on cancer 396 outcomes and overall mortality.

397 In conclusion, while we did not observe a significant difference in prostate cancer-specific 398 mortality or survival between Kentucky and Georgia, Kentucky's Medicaid expansion was 399 associated with a notable improvement in overall survival, evidenced by a significant reduction 400 in all-cause mortality compared to Georgia. This finding underscores the broader impact of 401 Medicaid expansion on health outcomes beyond cancer-specific measures, highlighting the 402 policy's potential to reduce overall mortality through improved healthcare access. However, 403 significant disparities persist, with Black individuals, low-income households, rural residents, 404 and unmarried individuals continuing to experience poorer outcomes in both cancer-specific and 405 overall survival. These results emphasize the need for targeted strategies to address these

406 ine	quities and	l ensure that	the benefits	of expanded	l healthcare c	coverage reach	the most
---------	-------------	---------------	--------------	-------------	----------------	----------------	----------

407 vulnerable populations.

408

412

415

418

422 423

424

425

428

432

435

409	REFERENCE
-----	-----------

410	1.	CDC NBaCEDP. Prostate Cancer Statistics 2024 [Available from:
411		https://www.cdc.gov/prostate-cancer/statistics/index.html.

- 413 2. American Cancer Society. Key Statistics for Prostate Cancer 2024 [Available from:
   414 <u>https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html</u>.
- 416 3. NIH NCI. Prostate Cancer Treatment (PDQ®)–Patient Version 2023 [Available from:
   417 <u>https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq.</u>
- 4. Showalter TN, Mishra MV, Bridges JF. Factors that influence patient preferences for
  prostate cancer management options: A systematic review. Patient Prefer Adherence.
  2015;9:899-911.
  - 5. Imber BS, Varghese M, Ehdaie B, Gorovets D. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020;17(1):28-40.
- 426 6. NIH NCI. Financial Burden of Cancer Care 2024 [Available from:
   427 <u>https://progressreport.cancer.gov/after/economic\_burden.</u>
- 429 7. Islami F, Miller KD, Siegel RL, Zheng Z, Zhao J, Han X, et al. National and State
  430 Estimates of Lost Earnings From Cancer Deaths in the United States. JAMA Oncology.
  431 2019;5(9):e191460-e.
- 433 8. Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer.
  434 Semin Oncol. 2013;40(3):244-58.
- 436 9. Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4 Suppl 5(Suppl 5):S3-s10.
- 438 10. Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival.
  439 Prostate Int. 2020;8(2):49-54.
- 440

441 442	11. Vince RA, Jr., Jiang R, Bank M, Quarles J, Patel M, Sun Y, et al. Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients:
443	A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(1):e2250416.
444	
445	12. Vince RA, Jr, Jiang R, Bank M, Quarles J, Patel M, Sun Y, et al. Evaluation of Social
446	Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients:
447	A Systematic Review and Meta-analysis. JAMA Network Open. 2023;6(1):e2250416-e.
448	12 Netional Anchines MD Medican and Medicaid Act (10(5) 2022 [Accellable frame
449	13. National Archives MD. Medicare and Medicaid Act (1965) 2022 [Available from:
450 451	<u>https://www.archives.gov/innestone-documents/inedicare-and-inedicard-act</u> .
452	14 Lyon SM Douglas IS Cooke CR Medicaid expansion under the Affordable Care Act
453	Implications for insurance-related disparities in pulmonary critical care and sleep Ann
454	Am Thorac Soc. 2014;11(4):661-7.
455	
456	15. Cohen WJ. Reflections on the enactment of Medicare and Medicaid. Health Care Financ
457	Rev. 1985;Suppl(Suppl):3-11.
458	
459	16. Kominski GF, Nonzee NJ, Sorensen A. The Affordable Care Act's Impacts on Access to
460	Insurance and Health Care for Low-Income Populations. Annu Rev Public Health.
461	2017;38:489-505.
462	17 Televenien CU Occurision & Monstoni D. Mitro N. Shylmon IN Debelmen IE, et al.
403 464	17. Takvorian SU, Oganisian A, Mamtani R, Mitra N, Shuiman LN, Bekelman JE, et al. Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status
465	Cancer Stage and Timely Treatment Among Patients With Breast Colon and Lung
466	Cancer JAMA Network Open 2020 <sup>3</sup> (2):e1921653-e
467	
468	18. Eguia E, Cobb AN, Kothari AN, Molefe A, Afshar M, Aranha GV, et al. Impact of the
469	Affordable Care Act (ACA) Medicaid Expansion on Cancer Admissions and Surgeries.
470	Ann Surg. 2018;268(4):584-90.
471	
472	19. NIH NCI. SEER Databases in SEER*Stat [Available from: https://seer.cancer.gov/data-
473	software/documentation/seerstat/.
474	
475	20. NIH NCI. Overview of the SEER Program [Available from:
470 477	<u>nups://seer.cancer.gov/about/overview.html</u> .
479 478	21 Alkhawaldeh & MAI Ravan & Abdalrahim & Musa & Eshah N at al Application and
479	Lise of Andersen's Behavioral Model as Theoretical Framework: A Systematic Literature
480	Review from 2012-2021 Iran I Public Health 2023:52(7):1346-54
100	100100 1011 2012 2021. hun 01 uone fromul. 2025,52(7).15 10 51.

481	
482 483 484 485	22. Krzyż EZ, Antunez Martinez OF, Lin HR. Uses of Andersen health services utilization framework to determine healthcare utilization for mental health among migrants-a scoping review. Front Public Health. 2023;11:1284784.
486 487 488	23. Forcasting SMa. Introduction To The Difference-In-Differences Regression Model [Available from: <u>https://timeseriesreasoning.com/contents/introduction-to-the-difference-in-differences-regression-model</u>
489 490 491 492	24. Janopaul-Naylor JR, Corriher TJ, Switchenko J, Hanasoge S, Esdaille A, Mahal BA, et al. Disparities in time to prostate cancer treatment initiation before and after the Affordable Care Act. Cancer Med. 2023;12(17):18258-68.
493 494 495 496	<ol> <li>Bhatia S, Landier W, Paskett ED, Peters KB, Merrill JK, Phillips J, et al. Rural-Urban Disparities in Cancer Outcomes: Opportunities for Future Research. J Natl Cancer Inst. 2022;114(7):940-52.</li> </ol>
497 498 499 500	<ol> <li>Miao Q, Wei Z, Liu C, Ye Y, Cheng G, Song Z, et al. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer. Frontiers in Oncology. 2023;13.</li> </ol>
501 502 503 504	<ol> <li>Liu W, Goodman M, Filson CP. Association of State-Level Medicaid Expansion With Treatment of Patients With Higher-Risk Prostate Cancer. JAMA Network Open. 2020;3(10):e2015198-e.</li> </ol>
505 506 507 508	<ol> <li>Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, et al. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett. 2022;531:71-82.</li> </ol>
510 511 512 513	29. Zeng H, Xu M, Xie Y, Nawrocki S, Morze J, Ran X, et al. Racial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study. eClinicalMedicine. 2023;62.
513 514 515 516 517	<ol> <li>Krajc K, Miroševič Š, Sajovic J, Klemenc Ketiš Z, Spiegel D, Drevenšek G, et al. Marital status and survival in cancer patients: A systematic review and meta-analysis. Cancer Med. 2023;12(2):1685-708.</li> </ol>
518 519	31. Lewis-Thames MW, Langston ME, Khan S, Han Y, Fuzzell L, Xu S, et al. Racial and Ethnic Differences in Rural-Urban Trends in 5-Year Survival of Patients With Lung,

520 521	Prostate, Breast, and Colorectal Cancers: 1975-2011 Surveillance, Epidemiology, and End Results (SEER). JAMA Network Open. 2022;5(5):e2212246-e.
522	
523	32. Maganty A, Byrnes ME, Hamm M, Wasilko R, Sabik LM, Davies BJ, et al. Barriers to
524	rural health care from the provider perspective. Rural Remote Health. 2023;23(2):7769.
525	
526	33. Afshar N, English DR, Milne RL. Factors Explaining Socio-Economic Inequalities in
527	Cancer Survival: A Systematic Review. Cancer Control. 2021;28:10732748211011956.
528	
529	34. Cella DF, Orav EJ, Kornblith AB, Holland JC, Silberfarb PM, Lee KW, et al.
530	Socioeconomic status and cancer survival. J Clin Oncol. 1991;9(8):1500-9.
531	
532	35. Courtemanche C, Marton J, Ukert B, Yelowitz A, Zapata D, Fazlul I. The three-year
533	impact of the Affordable Care Act on disparities in insurance coverage. Health Serv Res.
534	2019;54 Suppl 1(Suppl 1):307-16.
535	
536	36. Aljassim N, Ostini R. Health literacy in rural and urban populations: A systematic review.
537	Patient Educ Couns. 2020;103(10):2142-54.
538	
539	37. Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL.
540	Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in
541	Clinical Trials. JAMA Network Open. 2018;1(4):e181235-e.
542	
543	38. Forjaz G, Ries L, Devasia TP, Flynn G, Ruhl J, Mariotto AB. Long-term Cancer Survival
544	Trends by Updated Summary Stage. Cancer Epidemiol Biomarkers Prev.
545	2023;32(11):1508-17.
546	
547	39. Benitez JA, Creel L, Jennings J. Kentucky's Medicaid Expansion Showing Early Promise
548	On Coverage And Access To Care. Health Aff (Millwood). 2016;35(3):528-34.
549	
550	40. Martinez ME, Gomez SL, Canchola AJ, Oh DL, Murphy JD, Mehtsun W, et al. Changes
551	in Cancer Mortality by Race and Ethnicity Following the Implementation of the
552	Affordable Care Act in California. Front Oncol. 2022;12:916167.
553	
554	41. Hotca A, Bloom JR, Runnels J, Salgado LR, Cherry DR, Hsieh K, et al. The Impact of
555	Medicaid Expansion on Patients with Cancer in the United States: A Review. Curr Oncol.
556	2023;30(7):6362-73.
557	

42. Akinyemi OA, Weldeslase TA, Fasokun ME, Odusanya E, Mejulu EO, Salihu EY, et al. Causal Effects of the Affordable Care Act (ACA) Implementation on Non-Hodgkin's Lymphoma Survival: A Difference-in-Differences Analysis. Cureus. 2024;16(1):e52571.
43. Enyeji AM, Barengo NC, Ramirez G, Ibrahimou B, Arrieta A. Regional Variation in Health Care Utilization Among Adults With Inadequate Cardiovascular Health in the USA. Cureus. 2023;15(8):e44121.

566

Variables	Pre-A	ACA (2003-2009) (N=37,810)		Post-ACA (2015-2021) (N=30,412)			
variables	Georgia (N=26,772)	Kentucky (N=11,038)	P-value	Georgia (N=48,910)	Kentucky (N=19,312)	P-value	
Age (years; Mean $\pm$ SD)	57.3 ± 5.2	57.6± 5.0	< 0.01	$58.1 \pm 4.8$	$58.4\pm4.7$	< 0.01	
Age							
18-44yrs.	567 (2.1%)	163 (1.5%)	< 0.01	251 (1.1%)	72 (0.9%)	0.046	
45-64yrs.	26,205 (97.9%)	10,875 (98.5%)		21,887 (98.9%)	8,202 (99.1%)		
Race/Ethnicity			< 0.01			< 0.01	
White Person	16,158 (60.4%)	9,698 (87.9%)		10,366 (46.8%)	6,679 (80.7%)		
Black Person	9,895 (37.0%)	1,163 (10.5%)		10,566 (47.7%)	1,171 (14.2%)		
Hispanic Person	453 (1.7%)	57 (0.5%)		740 (3.3%)	80 (1.0%)		
Other	266 (1.0%)	120 (1.1%)		466 (2.1%)	344 (4.2%)		
Income			< 0.001			< 0.001	
<65K	12,679 (47.4%)	9,432 (85.5%)		9,739 (44.0%)	7,008 (84.7%)		
≥65K	14,093 (52.6%)	1,606 (14.6%)		12,399 (56.0%)	1,266 (15.3%)		
Marital Status			< 0.001			< 0.01	
Single	2,944 (11.0%)	754 (6.8%)		3,465 (15.7%)	968 (11.8%)		
Married	18,772 (70.1%)	7,358 (66.7%)		12,862 (58.3%)	4,883 (59.3%)		
Widowed	507 (1.9%)	196 (1.8%)		331 (1.5%)	162 (2.0%)		
Divorced	2,277 (8.5%)	997 (9.0%)		1,566 (7.1%)	845 (10.3%)		
Separated	273 (1.0%)	56 (0.5%)		197 (0.9%)	46 (0.6%)		
Unknown	1,988 (7.5%)	1,677 (15.2%)		3,649 (16.5%)	1,334 (16.2%)		
Metropolitan Status			< 0.001			< 0.001	
Rural areas not adjacent to metropolitan areas	1,081 (4.0%)	2,464 (22.3%)		930 (4.2%)	1,900 (23.0%)		
Rural areas adjacent to metropolitan areas	3,648 (13.6%)	1,809 (16.4%)		2,437 (11.0%)	1,273 (15.4%)		
Small metropolitan areas	4,037 (15.1%)	925 (8.4%)		3,020 (13.6%)	793 (9.6%)		

567 Table 1: Demographic, Clinical, and Treatment Characteristics of Individuals with Prostate Cancer in568 Georgia and Kentucky Before and After Medicaid Expansion in Kentucky in 2014.

Medium metropolitan areas	3,005 (11.2%)	1,704 (15.4%)		2,459 (11.1%)	1,262 (15.3%)	
Large metropolitan areas	15,001 (56.0%)	4,136 (37.5%)		13,292 (60.0%)	3,046 (36.8%)	
Stage at presentation			< 0.01			< 0.01
Localized	15,383 (85.8%)	5,731 (80.5%)		6,855 (77.2%)	2,395 (68.5%)	
Regional	1,802 (10.1%)	1,081 (15.2%0		1,237 (13.9%)	557 (15.9%)	
Distant	480 (2.7%)	196 (2.8%)		463 (5.2%)	160 (4.6%)	
Unknown	271 (1.5%)	109 (1.5%)		328 (3.7%)	384 (11.0%)	
Surgery, n (%)			< 0.001			< 0.01
Yes	14,217 (54.0%)	3,635 (35.7%)		13,867 (63.0%)	4,088 (54.8%)	
None/Unknown	12,135 (46.1%)	6,551 (64.3%)		8,143 (37.0%)	3,369 (45.2%)	
Chemotherapy, n (%)			0.345			0.106
Yes	191 (0.7%)	69 (0.6%)		445 (2.0%)	191 (2.3%)	
None/Unknown	26,581 (99.2%)	10,969 (99.4%)		21,693 (98.0%)	8,083 (97.7%)	
Radiotherapy, n (%)			< 0.01			< 0.01
Yes	7,994 (34.2%)	1,908 (19.5%)		5,210 (25.5%)	2,197 (27.6%)	
None/Unknown	15,390 (65.8%)	7,898 (80.5%)		15,242 (74.5%)	5,766 (72.4%)	

569

570 Table 2: Cox Proportional Hazards Model Assessing Factors Associated with Cancer-Specific Survival

571

among Individuals with Prostate Cancer.

Variables	Haz. Ratio	Std. Err.	Z	P>z	[95% Conf. Interval]	
State						
Kentucky (ref. Georgia)	1.181	0.039	5.050	0.000	1.107	1.259
ACA						
Post-ACA (ref. Pre-ACA)	0.901	0.042	-2.260	0.024	0.823	0.986
State x ACA						
Kentucky x Post-ACA	0.868	0.067	-1.850	0.065	0.747	1.009
Age						
18-44yrs.	Reference					
45-64yrs.	2.175	0.283	5.980	0.000	1.686	2.806
Race/Ethnicity						
White Person	Reference					
Black Person	1.103	0.031	3.480	0.001	1.044	1.166
Hispanics	0.983	0.103	-0.170	0.867	0.801	1.206
Other	0.741	0.162	-1.370	0.171	0.482	1.139
Household Median Income						
Income $\geq$ 64K (ref. < 64K)	0.878	0.030	-3.840	0.000	0.822	0.938
Marital Status						
Single	Reference					
Married	0.649	0.023	-11.960	0.000	0.605	0.697

Widowed	1.126	0.091	1.470	0.141	0.961	1.319
Divorced	0.994	0.046	-0.130	0.895	0.908	1.088
Separated	1.060	0.112	0.550	0.581	0.861	1.305
Unknown	0.751	0.040	-5.430	0.000	0.678	0.833
Metropolitan Status						
Rural areas not adjacent to metropolitans	Reference					
Rural areas adjacent to metropolitans	0.964	0.045	-0.770	0.441	0.880	1.058
Small metropolitan areas	0.819	0.041	-3.990	0.000	0.743	0.904
Medium metropolitan areas	0.776	0.039	-5.060	0.000	0.703	0.856
Large metropolitan areas	0.713	0.033	-7.340	0.000	0.652	0.781
Grade						
Localized	Reference					
Regional	1.133	0.099	1.430	0.154	0.954	1.345
Distant	3.482	0.387	11.230	0.000	2.801	4.329
Stage at Presentation						
Stage I	Reference					
Stage II	1.449	0.168	3.200	0.001	1.155	1.819
Stage III	2.135	0.318	5.100	0.000	1.595	2.858
Stage IV	4.047	0.625	9.060	0.000	2.991	5.477
Prostatectomy	0.473	0.017	-21.050	0.000	0.441	0.507
Chemotherapy	1.421	0.097	5.130	0.000	1.243	1.625
Radiation	1.017	0.032	0.530	0.598	0.956	1.082

572

573 Table 3: Cox Proportional Hazards Model Assessing Factors Associated with Overall Survival among574 Individuals with Prostate Cancer.

Variables	Haz. Ratio	Std. Err.	Z	P>z	[95% Conf. Interval]	
State						
Kentucky (ref. Georgia)	1.112	0.068	1.750	0.080	0.987	1.253
ACA						
Post-ACA (ref. Pre-ACA)	0.780	0.054	-3.610	0.000	0.682	0.893
State x ACA						
Kentucky x Post-ACA	0.711	0.087	-2.770	0.006	0.559	0.905
Age						
18-44yrs.	Reference					
45-64yrs.	1.440	0.266	1.980	0.048	1.003	2.068
Race/Ethnicity						
White	Reference					
Black	1.103	0.055	1.970	0.049	1.000	1.215

Hispanics	0.862	0.154	-0.830	0.406	0.608	1.223
Other	1.229	0.374	0.680	0.499	0.676	2.233
Household Median Income						
Income $\geq$ 64K (ref. < 64K)	0.935	0.055	-1.140	0.253	0.832	1.049
Marital Status						
Single	Reference					
Married	0.653	0.040	-6.980	0.000	0.580	0.736
Widowed	1.065	0.148	0.450	0.652	0.810	1.399
Divorced	0.834	0.066	-2.310	0.021	0.714	0.973
Separated	0.835	0.154	-0.980	0.330	0.581	1.200
Unknown	0.863	0.078	-1.630	0.102	0.723	1.030
Metropolitan Status						
Rural areas not adjacent to metropolitan areas	Reference					
Rural areas adjacent to metropolitan areas	0.915	0.077	-1.050	0.294	0.775	1.080
Small metropolitan areas	0.752	0.068	-3.140	0.002	0.629	0.898
Medium metropolitan areas	0.816	0.073	-2.270	0.023	0.684	0.973
Large metropolitan areas	0.738	0.062	-3.630	0.000	0.626	0.870
Grade						
Localized	Reference					
Regional	1.269	0.268	1.130	0.258	0.839	1.919
Distant	4.357	0.981	6.540	0.000	2.803	6.773
Stage at Presentation						
Stage I	Reference					
Stage II	3.203	1.152	3.240	0.001	1.583	6.482
Stage III	10.432	4.363	5.610	0.000	4.596	23.677
Stage IV	26.988	11.333	7.850	0.000	11.851	61.461
Prostatectomy	0.378	0.025	-14.840	0.000	0.332	0.430
Chemotherapy	1.622	0.127	6.180	0.000	1.391	1.891
Radiation	1.204	0.060	3.740	0.000	1.092	1.327

576 Table 4: Predicted Probabilities of Cancer-Specific Survival Among Individuals Prostate Cancer

Variables	ALL	White	Black	Hispanic	NHAPI	Native Americans
Georgia x	5.41 (1.55-	5.21 (1.49-	5.74 (1.61-	4.49 (0.94-	6.40 (0.44-	
Post-ACA	9.28)	8.93)	9.88)	8.04)	12.36)	2.42 (-2.63-7.47)
Georgia x	4.22 (1.10-	4.07 (1.06-	4.48 (1.15-	3.51 (0.67-	5.00 (0.25-	
Pre-ACA	7.35)	7.07)	7.82)	6.35)	9.75)	1.89 (-2.06-5.84)
Kentucky						
x Post-	6.02 (1.63-	5.79 (1.58-	6.39 (1.69-	5.00 (0.98-	7.12 (0.41-	
ACA	10.41)	10.00)	11.09)	9.01)	13.83)	2.69 (-2.94-9.32)

Kentucky						
x Pre-	3.34 (0.80-	3.21 (0.78-	3.54 (0.82-	2.77 (0.47-	3.95 (0.13-	
ACA	5.88)	5.65)	6.27)	5.08)	7.77)	1.49 (-1.64-4.63)

578 Table 5: Predicted Probabilities of Cancer-Specific Survival Among Individuals Prostate Cancer

Variables	ALL	White	Black	Hispanic	NHAPI	Native Americans
Georgia x Post-ACA	1.06 (0.81-1.31)	1.02 (0.78-1.26)	1.13 (0.86-1.40)	1.00 (0.69-1.32)	0.76 (0.39-1.13)	0.45 (-0.18-1.07)
Georgia x Pre-ACA	0.95 (0.70-1.21)	0.92 (0.67-1.17)	1.02 (0.74-1.29)	0.91 (0.60-1.21)	0.68 (0.34-1.03)	0.40 (-0.17-0.97)
Kentucky x Post-ACA	1.25 (0.94-1.56)	1.21 (0.91-1.51)	1.33 (0.99-1.67)	1.19 (0.81-1.57)	0.89 (0.45-1.34)	0.53 (-0.21-1.27)
Kentucky x Pre-ACA	0.98 (0.70-1.26)	0.94 (0.67-1.22)	1.04 (0.73-1.35)	0.93 (0.60-1.25)	0.70 (0.34-1.06)	0.41 (-0.17-0.99)

# 581 Table 6: DID Output for Cancer-Specific Survival by Race/Ethnicity

Race/Ethnicity	Std. Err.	Z	P>z	[95% Conf. Interval]	
All	-1.492	0.770	0.053	-3.000	0.017
White Person	-1.436	0.740	0.052	-2.885	0.014
Blacks Person	-1.583	0.820	0.054	-3.191	0.025
Hispanic Person	-1.238	0.671	0.065	-2.554	0.078
Asian & Pacific Islanders	-1.764	1.059	0.096	-3.839	0.311
Native Americans	-0.667	0.753	0.376	-2.142	0.808

Table 7: DID Output for Overall Survival by Race/Ethnicity

Race/Ethnicity	Coefficient	Std. Err	P>z	[95% Conf. Interval]	
All	-0.168	0.081	0.039	-0.326	-0.009
White Person	-0.162	0.078	0.039	-0.315	-0.008
Black Person	-0.179	0.086	0.039	-0.348	-0.009
Hispanic Person	-0.159	0.079	0.043	-0.313	-0.005
Asian & Pacific Islanders	-0.120	0.064	0.060	-0.245	0.005
Native Americans	-0.071	0.061	0.245	-0.190	0.048